Summit Therapeutics Inc.
SMMT
$18.22
-$0.69-3.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -312.05% | -836.84% | -44.72% | -67.37% | -164.50% |
| Total Depreciation and Amortization | 110.00% | 85.00% | -7.41% | -26.67% | -37.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 670.97% | 1,859.79% | -13.25% | 55.11% | 685.51% |
| Change in Net Operating Assets | -12.36% | 614.21% | -247.36% | -108.00% | 114.64% |
| Cash from Operations | -207.23% | -102.24% | -102.99% | -150.13% | -103.38% |
| Capital Expenditure | -22.41% | 100.00% | -10,450.00% | -600.00% | -9.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | 175.40% | 707.71% | 37.85% | -3,062.16% |
| Cash from Investing | 99.93% | 175.37% | 705.75% | 37.83% | -3,015.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.91% | -98.89% | 1,482.89% | -87.08% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.44% | -98.89% | 1,482.89% | -477.67% | 89,044.98% |
| Foreign Exchange rate Adjustments | -80.70% | 408.33% | 205.56% | -139.71% | 167.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -190.77% | 362.80% | 1,186.78% | -76.72% | 456.60% |